Alliance Global Partners initiated coverage of Vivos Therapeutics with a Buy rating and $8.25 price target. Vivos is developing, manufacturing, and selling nighttime dental appliances for the treatment of obstructive sleep apnea, or OSA, and the firm expects strong revenue growth for Vivos CARE following the recent label expansion to include severe patients. However, it notes that it views shares as “highly speculative as the company is not yet profitable and carries higher financial risk.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VVOS:
- Vivos Therapeutics Secures $8M Through Strategic Equity Deals
- Vivos Therapeutics announces exercise of warrants for $4M in gross proceeds
- Vivos Therapeutics highlights favorable market developments
- Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities
- Vivos Therapeutics seeing positive preliminary metrics following FDA clearance
